Genome wide association study to understand the role of Clusterin (CLU - Endophenotype for AD) in Alzheimer's Disease. Imputed data consists of 6,015,512 SNPS using 1000 Genomes data (June 2011 release) CEU (build 37) as a reference. This study involves 673 individuals (400 ADRC, 273 ADNI). We provide access to 400 ADRC subjects, remaining data for 273 ADNI subjects can be obtained at adni.loni.usc.edu.
The data provided in this dataset has genotype information for 50 individuals, data for the remaining 350 subjects are available through NIAGADS dataset NG00035.
NIAGADS staff is collecting Genomic Data Sharing (GDS) documentation for this dataset. Until we know how the study's cohort's Institutional Review Board wants the data to be shared, the data cannot be distributed. Information about GDS is available at https://osp.od.nih.gov/scientific-sharing/genomic-data-sharing/. If you have questions about GDS, you may contact Dr. Marilyn Miller, firstname.lastname@example.org. In the meantime, you may still submit a request for this dataset, but it will not be distributed until GDS documentation is complete.
Total subjects- 673
Knight ADRC- 400
ADNI- 273 (apply for access through ADNI)
The NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) is supported by a collaborative agreement from the National Institute on Aging, U24AG041689.
NG00050, NG00052: This work was supported by Pfizer and grants from the National Institutes of Health (R01-AG044546, P01-AG003991), and the Alzheimer's Association (NIRG-11–200110). This research was conducted while Carlos Cruchaga was a recipient of a New Investigator Award in Alzheimer's disease from the American Federation for Aging Research. Carlos Cruchaga is a recipient of a BrightFocus Foundation Alzheimer's Disease Research Grant (A2013359S). The recruitment and clinical characterization of research participants at Washington University were supported by NIHP50 AG05681, P01 AG03991, and P01 AG026276. Some of the samples used in this study were genotyped by the ADGC and GERAD. ADGC is supported by grants from the NIH (#U01AG032984) and GERAD from the Wellcome Trust (GR082604MA) and the Medical Research Council (G0300429). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace; Merck; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.